Replies to post #37465 on Avid Bioservices Inc (CDMO)

[Charlie Stein]

"Cotara was concentrated in the brain tumor (246-671 cGy/mCi), with minimal exposure to the contralateral healthy brain (0.7-1.6 cGy/mCi). Mean tumor-to-body dose ratio was 605 and ranged 319-797."

Such a high dose ratio is outstanding. Antibodies from other researchers have shown tumor-to-normal dose ratios of 38 for non-Hodgkins lymphoma, http://www.ncbi.nlm.nih.gov/pubmed/10740649 , 54 for gastrointestinal cancers, http://www.redorbit.com/news/display?id=144309&source=r_health

Cotara is providing a ratio ten times higher, showing tremendous safety and suggesting high efficacy.

Unfortunately, it's not as though this is completely new information. The numbers are a little different, but this type of incredible performance has been reported in the past:
http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/2072

We need to partner this drug.